Literature DB >> 18644769

Acoustic determination of early stages of intravascular blood coagulation.

Svetlana G Uzlova1, Konstantin G Guria, Georgy Th Guria.   

Abstract

The blood coagulation system (BCS) is a complex biological system playing a principal role in the maintenance of haemostasis. Insufficient activity of the BCS may lead to bleeding and blood loss (e.g. in the case of haemophilia). On the other hand, excessive activity may cause intravascular blood coagulation, thromboses and embolization. Most of the methods currently used for BCS monitoring suffer from the major disadvantage of being invasive. The purpose of the present work is to demonstrate the feasibility of using ultrasonic methods for non-invasive registration of the early stages of blood coagulation processes in intensive flows. With this purpose, a special experimental set-up was designed, facilitating the simultaneous detection of optical and acoustic signals during the clotting process. It was shown that (i) as microemboli appear in the flow during the early stage of blood coagulation, the intensity of the Doppler signal increases twofold, and (ii) microemboli formation in the early stages of blood clotting always reveals itself through an acoustic contrast. Both of these effects are well defined, so we hope that they may be used for non-invasive BCS monitoring in clinical practice.

Entities:  

Mesh:

Year:  2008        PMID: 18644769     DOI: 10.1098/rsta.2008.0109

Source DB:  PubMed          Journal:  Philos Trans A Math Phys Eng Sci        ISSN: 1364-503X            Impact factor:   4.226


  2 in total

1.  Control of fibrinolytic drug injection via real-time ultrasonic monitoring of blood coagulation.

Authors:  Dmitry A Ivlev; Shakhla N Shirinli; Konstantin G Guria; Svetlana G Uzlova; Georgy Th Guria
Journal:  PLoS One       Date:  2019-02-27       Impact factor: 3.240

2.  Blood clot detection using magnetic nanoparticles.

Authors:  Hafsa Khurshid; Bruce Friedman; Brent Berwin; Yipeng Shi; Dylan B Ness; John B Weaver
Journal:  AIP Adv       Date:  2017-02-16       Impact factor: 1.548

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.